Patients with MS often suffer from pelvic-organ dysfunctions, i.e. lower urinary tract (LUT), bowel and sexual dysfunction, aside their cerebral affection. Sacral neuromodulation (SNM) is a reversible minimal invasive procedure affecting the function of the aforementioned pelvic organs. Changes in bladder, bowel and sexual function will be monitored.~Primary outcome:~To evaluate the success of SNM for LUTD in patients with MS defined as improvement of at least 50% improvement of patient symptoms.~Secondary outcome:~Changes in urodynamic parameters~Bowel function~Sexual function~Quality of life~Adverse events~Implantation Characteristics~Data will be collected at inclusion = baseline 1. After three weeks evaluation = baseline 2 for implantation of pulse generator (IPG).~After one week implantation of IPG and randomization to either IPG on or IPG off and followed for four months, including a follow-up after the first month.~The evaluation after four months = baseline 3 and is the end of randomized clinical trial (RCT).~The time frame of the RCT is five months~The study converts into an open label study where all the patients have the IPG ON and are followed for another three months.~The overall time frame is 8 months. The patients will be followed-up every 6 months for a total of 5 years.
A randomized controlled trial (RCT). To evaluate the efficacy of SNM for patients with Multiple Sclerosis (MS) having refractory neurogenic lower urinary tract dysfunction (nLUTD). After a two-step procedure patients (n=60) with more than 50% improvement in the key bladder diary variables will be randomized after implantation of pulse generator (IPG) for sacral neuromodulation, ON or OFF, for four months.